A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy

E. Czeizel, M. Rockenbauer, H. T. Sørensen, J. Olsen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To study human teratogenic potential of furazidine treatment during pregnancy. Design: Pair analysis of cases with congenital abnormalities and matched population controls. Setting: The Hungarian Case- Control Surveillance of Congenital Abnormalities. Participants: 38,151 pregnant women who had newborn infants without any defects (population control group) and 22.865 pregnant women who had newborns or fetuses with congenital abnormalities between 1980 and 1996. Results: In the case group, 157 (0.7%) and in the control group, 254 (0.7%) pregnant women were treated with furazidine. The case-control pair analysis did not indicate a teratogenic potential of furazidine use during the second to third months of gestation, i.e. in the critical period for major congenital abnormalities. Conclusion: Treatment with furazidine during pregnancy did not show teratogenic risk to the fetus.

Original languageEnglish
Pages (from-to)257-263
Number of pages7
JournalClinical Nephrology
Volume53
Issue number4
Publication statusPublished - 2000

Fingerprint

Nitrofurans
Case-Control Studies
Pregnant Women
Pregnancy
Population Control
Population
Fetus
Newborn Infant
Control Groups
Therapeutics
Population Groups

Keywords

  • Case-control analysis
  • Congenital abnormalities
  • Furazidine
  • Human teratogenic potential
  • Nitrofuran-derivatives

ASJC Scopus subject areas

  • Nephrology

Cite this

A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy. / Czeizel, E.; Rockenbauer, M.; Sørensen, H. T.; Olsen, J.

In: Clinical Nephrology, Vol. 53, No. 4, 2000, p. 257-263.

Research output: Contribution to journalArticle

@article{528eddb2090b45ae859b8fb83ba35d81,
title = "A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy",
abstract = "Objective: To study human teratogenic potential of furazidine treatment during pregnancy. Design: Pair analysis of cases with congenital abnormalities and matched population controls. Setting: The Hungarian Case- Control Surveillance of Congenital Abnormalities. Participants: 38,151 pregnant women who had newborn infants without any defects (population control group) and 22.865 pregnant women who had newborns or fetuses with congenital abnormalities between 1980 and 1996. Results: In the case group, 157 (0.7{\%}) and in the control group, 254 (0.7{\%}) pregnant women were treated with furazidine. The case-control pair analysis did not indicate a teratogenic potential of furazidine use during the second to third months of gestation, i.e. in the critical period for major congenital abnormalities. Conclusion: Treatment with furazidine during pregnancy did not show teratogenic risk to the fetus.",
keywords = "Case-control analysis, Congenital abnormalities, Furazidine, Human teratogenic potential, Nitrofuran-derivatives",
author = "E. Czeizel and M. Rockenbauer and S{\o}rensen, {H. T.} and J. Olsen",
year = "2000",
language = "English",
volume = "53",
pages = "257--263",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "4",

}

TY - JOUR

T1 - A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy

AU - Czeizel, E.

AU - Rockenbauer, M.

AU - Sørensen, H. T.

AU - Olsen, J.

PY - 2000

Y1 - 2000

N2 - Objective: To study human teratogenic potential of furazidine treatment during pregnancy. Design: Pair analysis of cases with congenital abnormalities and matched population controls. Setting: The Hungarian Case- Control Surveillance of Congenital Abnormalities. Participants: 38,151 pregnant women who had newborn infants without any defects (population control group) and 22.865 pregnant women who had newborns or fetuses with congenital abnormalities between 1980 and 1996. Results: In the case group, 157 (0.7%) and in the control group, 254 (0.7%) pregnant women were treated with furazidine. The case-control pair analysis did not indicate a teratogenic potential of furazidine use during the second to third months of gestation, i.e. in the critical period for major congenital abnormalities. Conclusion: Treatment with furazidine during pregnancy did not show teratogenic risk to the fetus.

AB - Objective: To study human teratogenic potential of furazidine treatment during pregnancy. Design: Pair analysis of cases with congenital abnormalities and matched population controls. Setting: The Hungarian Case- Control Surveillance of Congenital Abnormalities. Participants: 38,151 pregnant women who had newborn infants without any defects (population control group) and 22.865 pregnant women who had newborns or fetuses with congenital abnormalities between 1980 and 1996. Results: In the case group, 157 (0.7%) and in the control group, 254 (0.7%) pregnant women were treated with furazidine. The case-control pair analysis did not indicate a teratogenic potential of furazidine use during the second to third months of gestation, i.e. in the critical period for major congenital abnormalities. Conclusion: Treatment with furazidine during pregnancy did not show teratogenic risk to the fetus.

KW - Case-control analysis

KW - Congenital abnormalities

KW - Furazidine

KW - Human teratogenic potential

KW - Nitrofuran-derivatives

UR - http://www.scopus.com/inward/record.url?scp=0034128074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034128074&partnerID=8YFLogxK

M3 - Article

VL - 53

SP - 257

EP - 263

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 4

ER -